Production (Stage)
Vanda Pharmaceuticals Inc.
VNDA
$4.33
$0.092.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.43% | 17.48% | 22.76% | 9.59% | -24.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.43% | 17.48% | 22.76% | 9.59% | -24.06% |
| Cost of Revenue | 2.35% | -25.14% | -16.72% | -21.89% | -27.94% |
| Gross Profit | 5.67% | 21.01% | 26.15% | 12.18% | -23.74% |
| SG&A Expenses | 66.47% | 66.36% | 51.71% | 39.00% | -16.67% |
| Depreciation & Amortization | -13.18% | 83.84% | 360.79% | 363.49% | 432.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.62% | 21.20% | 30.89% | 23.91% | -6.28% |
| Operating Income | -344.27% | -44.90% | -83.49% | -253.89% | -560.83% |
| Income Before Tax | -701.20% | -291.15% | -5,103.33% | -312.81% | -184.37% |
| Income Tax Expenses | -1,420.08% | -314.48% | -257.98% | -193.10% | -122.76% |
| Earnings from Continuing Operations | -611.38% | -104.67% | -3,986.13% | -397.24% | -227.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -611.38% | -104.67% | -3,986.13% | -397.24% | -227.49% |
| EBIT | -344.27% | -44.90% | -83.49% | -253.89% | -560.83% |
| EBITDA | -456.91% | -39.93% | -66.81% | -261.06% | -362.19% |
| EPS Basic | -601.81% | -101.92% | -3,908.33% | -392.83% | -225.96% |
| Normalized Basic EPS | -690.10% | -27.29% | -5,053.85% | -309.93% | -183.33% |
| EPS Diluted | -601.81% | -80.00% | -3,908.33% | -401.89% | -225.96% |
| Normalized Diluted EPS | -690.10% | -27.29% | -5,053.85% | -309.93% | -183.89% |
| Average Basic Shares Outstanding | 1.33% | 1.35% | 1.29% | 1.33% | 1.31% |
| Average Diluted Shares Outstanding | 1.33% | 1.35% | 1.16% | 1.19% | 0.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |